Successful subcutaneous desensitization in a patient with allergy to ixekizumab

Because of a partial response to the treatment and the continued negative effect on the patient's quality of life, all treatments were interrupted. [...]the cumulative dose of 79.55 mg was reached without any other reaction. Pretreatment and/or posttreatment could have helped to avoid local rea...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 6; no. 5; pp. 1761 - 1762
Main Authors:	Jimenez, Ruth Barranco, Vera, Daiana Guillen, Rivera-Díaz, Raquel, Cortijo-Cascajares, Susana, Ballesteros, Ruth Mielgo, Pastor, María del Carmen Diéguez
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-09-2018 Elsevier Limited
Subjects:	Allergies Desensitization (Psychology) Drug dosages Monoclonal antibodies Patients Pruritus Psoriasis Quality of life Skin tests
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Because of a partial response to the treatment and the continued negative effect on the patient's quality of life, all treatments were interrupted. [...]the cumulative dose of 79.55 mg was reached without any other reaction. Pretreatment and/or posttreatment could have helped to avoid local reactions, but the positive skin test result to ixekizumab indicated an immune mechanism as well as the possibility of systemic reaction. [...]in the absence of therapeutic options to improve the patient's quality of life, desensitization to ixekizumab was the most effective therapeutic treatment.
ISSN:	2213-2198 2213-2201
DOI:	10.1016/j.jaip.2017.12.036